In particular, they observed a statistically significant greater burden of missense mutations among men, even after adjusting for age at diagnosis, primary tumor site, stage at diagnosis, site of sequenced tumor, history of neoadjuvant treatment, and BRAF and NRAS mutation status. The gene discussed is NRAS; the disease is neoplasm.